Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19697161 | 0.94 | LIMK1 (0.33) | KCNH2KCNA5TDP1L3MBTL1LIMK1 | |
| SCHEMBL19831937 | 0.88 | KDM4E (0.37) | LIMK1ALDH1A1SCDSCD5 | |
| SCHEMBL19406631 | 0.84 | KCNH2 (0.36) | KCNH2KCNA5TDP1L3MBTL1LIMK1 | |
| SCHEMBL19406662 | 0.83 | TDP1 (0.34) | NR1I2KCNH2KCNA5TDP1L3MBTL1 | |
| SCHEMBL26972097 | 0.80 | NR1I2 (0.39) | NR1I2KCNH2 | |
| SCHEMBL22260641 | 0.78 | NR1I2 (0.38) | NR1I2KCNH2KCNA5TDP1L3MBTL1 | |
| SCHEMBL22260121 | 0.78 | NR1I2 (0.38) | NR1I2KCNH2KCNA5TDP1L3MBTL1 | |
| SCHEMBL23219779 | 0.78 | NR1I2 (0.38) | NR1I2KCNH2KCNA5TDP1L3MBTL1 | |
| SCHEMBL21423150 | 0.78 | CYP1A2 (0.39) | NR1I2KCNH2 | |
| SCHEMBL22260101 | 0.75 | NR1I2 (0.38) | NR1I2KCNH2KCNA5TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030007-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20170275260-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030007-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA6 | NR1I2 946/4885KCNH2 1353/4885KCNA5 1237/4885 |
| US-20170275260-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA6 | NR1I2 946/4885KCNH2 1353/4885KCNA5 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.